Rubicon Research Ltd
Rubicon Research Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #17 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Strong growth trajectory continues with broad-based demand across the product portfolio. Rubicon Research demonstrated strong growth momentum in Q4 FY26 with revenue up 44% YoY and EBITDA up 67% YoY; PAT grew 112% YoY.
From Rubicon Research Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Strong growth trajectory continues with broad-based demand across the product portfolio.
- Revenue for Q4 FY26 showed a 44% year-on-year growth, with sequential growth of around 8%.
- The company expects sustained demand and increased outsourcing for at least the next couple of quarters.
- Upcoming 24 product filings under US FDA review indicate a robust pipeline, with launches expected over the next 12 to 18 months.
- Pithampur facility ramp-up anticipated within 12 to 18 months post FDA inspection, enhancing internal manufacturing capacity.
- Capex of around INR 300 crores planned over the next two years to support growth and capacity expansion.
2 more points from Rubicon Research Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Rubicon Research Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex guidance for the next two years is projected to be close to INR 300 crores across various sites (Page 14).
- The Pithampur facility will be ramped up in the coming year to meet the strong demand (Page 14).
- Capex philosophy: capex will lag sustained demand; capex incurred only after proven long-term demand to avoid overcapacity (Page 14).
- Recent capex includes acquisition of the Pithampur facility and additional investments (Page 4).
2 more points from Rubicon Research Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rubicon Research Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Rubicon Research has a strong revenue visibility with broad-based demand across its portfolio.
- There are 24 products currently under review with the US FDA, indicating a robust pending approval pipeline.
- These 24 products under FDA review are expected to launch over the next 12 to 18 months, contributing to growth.
- Inventory levels have increased as part of preparation for upcoming product launches.
2 more points from Rubicon Research Ltd's call on order book
Create a free account to keep reading this call
Rubicon Research Ltd — Quarterly revenue & net profit
Q4 FY26 figures are not in this chart yet. Latest shown: Dec 2025 (Q3 FY26). The Q4 FY26 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹476 Cr, net profit ₹73 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rubicon Research Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Rubicon Research Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Rubicon Research Ltd Q4 FY26 results?
Strong growth trajectory continues with broad-based demand across the product portfolio. Rubicon Research demonstrated strong growth momentum in Q4 FY26 with revenue up 44% YoY and EBITDA up 67% YoY; PAT grew 112% YoY.
What is Rubicon Research Ltd share price analysis?
Rubicon Research Ltd currently shows a neutral. The stock trades at a P/E of 105.5 with a market cap of ₹26,041 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rubicon Research Ltd planning capital expenditure?
Capex guidance for the next two years is projected to be close to INR 300 crores across various sites (Page 14).
Keep Rubicon Research Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.